Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Wher...

Descripción completa

Detalles Bibliográficos
Autores principales: Houde, Vanessa P., Brûlé, Sophie, Festuccia, William T., Blanchard, Pierre-Gilles, Bellmann, Kerstin, Deshaies, Yves, Marette, André
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874694/
https://www.ncbi.nlm.nih.gov/pubmed/20299475
http://dx.doi.org/10.2337/db09-1324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874694/
https://www.ncbi.nlm.nih.gov/pubmed/20299475
http://dx.doi.org/10.2337/db09-1324

Ejemplares similares